Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare ConferenceGlobeNewsWire • 03/06/24
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 02/29/24
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key MetricsZacks Investment Research • 02/26/24
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/20/24
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After BunionectomyGlobeNewsWire • 02/15/24
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.GlobeNewsWire • 02/07/24
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 RevenuesGlobeNewsWire • 01/04/24
Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block IndicationsGlobeNewsWire • 11/10/23
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in NovemberGlobeNewsWire • 11/07/23
Pacira (PCRX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 11/02/23